Johannes G. van der Hoeven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes G. van der Hoeven has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Wilson Farid Abdo
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications - Joris Lemson
Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publications - Nichon E. Jansen
Department of Policy and Research, Dutch Transplant Foundation, Leiden, The Netherlands
4 shared publications - Angela M M Kotsopoulos
Department of Intensive Care, Elisabeth Tweesteden Hospital, Tilburg, The Netherlands
3 shared publications - Ewald Maria Bronkhorst
Department of Dentistry, Radboud Institute for Health Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
3 shared publications - Peter Pickkers
Department of Intensive Care, Radboud University Medical Centre, Nijmegen, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-13
The effect of mechanical ventilation on respiratory muscle echogenicity in critically ill children: an observational cohort study
Respiratory muscle weakness is common in critically ill children. Changes in respiratory muscle structure play pivotal role in the development of weakness. Echogenicity is a non-invasive marker to detect structural changes in skeletal muscles. In this study, we evaluated respiratory muscle echogenicity in critically ill ventilated children at PICU admission compared to a control group and its change over time. Secondary, we explored its association with clinical parameters and outcome. Two cohorts were studied: a secondary analysis of a prospective longitudinal observational cohort study in mechanically ventilated children (n = 32) and a prospective control group (n = 13) for obtaining reference values. Ultrasound images of the diaphragm and expiratory muscles were analysed. Muscle echogenicity, muscle thickness, muscle thickening fraction, clinical parameters (inflammation, fluid balance and protein intake) and clinical outcome measurements (ventilation free days, extubation failure and 28-day mortality) were collected. The analysis included 174 diaphragm ultrasounds and 144 expiratory respiratory muscles ultrasounds. Echogenicity at PICU admission was not different from controls; for the diaphragm: 27.3 [20.0–32.0] vs 26.3 [19.3–29.3] (P = 0.488), m. obliquus externus: 32.2 [25.5–37.9] vs 34.0 [28.0–51.3] (P = 0.166), m. obliquus interna: 29.8 [25.8–38.8] vs 33.0 [27.8–39.3] (P = 0.390), m. transversus: 30.0 [20.8–38.8] vs 32.3 [24.7–37.0] (P = 0.762), respectively. There was no increase in respiratory muscle echogenicity after four days of mechanical ventilation, though a substantial interindividual variation existed. No correlation was found between changes in echogenicity and changes in muscle thickness, thickening fraction and echogenicity on day four of mechanical ventilation, or clinical outcome. The intra-observer repeatability of the echogenicity for all the respiratory muscles was excellent (all ≥ 0.97). In critically ill children, four days of mechanical ventilation does not result in an increase in respiratory muscle echogenicity. Our findings suggest that short periods of mechanical ventilation with relatively low ventilator setting in moderate critically ill children do not lead to large structural changes in the respiratory muscles.
- 2 July 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-13
Open AccessThe effect of mechanical ventilation on respiratory muscle echogenicity in critically ill children: an observational cohort study
Respiratory muscle weakness is common in critically ill children. Changes in respiratory muscle structure play pivotal role in the development of weakness. Echogenicity is a non-invasive marker to detect structural changes in skeletal muscles. In this study, we evaluated respiratory muscle echogenicity in critically ill ventilated children at PICU admission compared to a control group and its change over time. Secondary, we explored its association with clinical parameters and outcome. Two cohorts were studied: a secondary analysis of a prospective longitudinal observational cohort study in mechanically ventilated children (n = 32) and a prospective control group (n = 13) for obtaining reference values. Ultrasound images of the diaphragm and expiratory muscles were analysed. Muscle echogenicity, muscle thickness, muscle thickening fraction, clinical parameters (inflammation, fluid balance and protein intake) and clinical outcome measurements (ventilation free days, extubation failure and 28-day mortality) were collected. The analysis included 174 diaphragm ultrasounds and 144 expiratory respiratory muscles ultrasounds. Echogenicity at PICU admission was not different from controls; for the diaphragm: 27.3 [20.0–32.0] vs 26.3 [19.3–29.3] (P = 0.488), m. obliquus externus: 32.2 [25.5–37.9] vs 34.0 [28.0–51.3] (P = 0.166), m. obliquus interna: 29.8 [25.8–38.8] vs 33.0 [27.8–39.3] (P = 0.390), m. transversus: 30.0 [20.8–38.8] vs 32.3 [24.7–37.0] (P = 0.762), respectively. There was no increase in respiratory muscle echogenicity after four days of mechanical ventilation, though a substantial interindividual variation existed. No correlation was found between changes in echogenicity and changes in muscle thickness, thickening fraction and echogenicity on day four of mechanical ventilation, or clinical outcome. The intra-observer repeatability of the echogenicity for all the respiratory muscles was excellent (all ≥ 0.97). In critically ill children, four days of mechanical ventilation does not result in an increase in respiratory muscle echogenicity. Our findings suggest that short periods of mechanical ventilation with relatively low ventilator setting in moderate critically ill children do not lead to large structural changes in the respiratory muscles.
- Open Access
Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol
Introduction: Postoperative cognitive dysfunction occurs frequently after coronary artery bypass grafting (CABG). The underlying mechanisms remain poorly understood, but neuroinflammation might play a pivotal role. We hypothesise that systemic inflammation induced by the surgical trauma could activate the innate immune (glial) cells of the brain. This could lead to an exaggerated neuroinflammatory cascade, resulting in neuronal dysfunction and loss of neuronal cells. Therefore, the aims of this study are to assess neuroinflammation in vivo presurgery and postsurgery in patients undergoing major cardiac surgery and investigate whether there is a relationship of neuroinflammation to cognitive outcomes, changes to brain structure and function, and systemic inflammation. Methods and analysis: The FOCUS study is a prospective, single-centre observational study, including 30 patients undergoing elective on-pump CABG. Translocator protein (TSPO) positron emission tomography neuroimaging will be performed preoperatively and postoperatively using the second generation tracer 18 F-DPA-714 to assess the neuroinflammatory response. In addition, a comprehensive cerebral MRI will be performed presurgery and postsurgery, in order to discover newly developed brain and vascular wall lesions. Up to 6 months postoperatively, serial extensive neurocognitive assessments will be performed and blood will be obtained to quantify systemic inflammatory responses and peripheral immune cell activation. Ethics and dissemination: Patients do not benefit directly from engaging in the study, but imaging neuroinflammation is considered safe and no side effects are expected. The study protocol obtained ethical approval by the Medical Research Ethics Committee region Arnhem-Nijmegen. This work will be published in peer-reviewed international medical journals and presented at medical conferences. Trial registration number: NCT04520802 .
Open AccessNeuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol
Introduction: Postoperative cognitive dysfunction occurs frequently after coronary artery bypass grafting (CABG). The underlying mechanisms remain poorly understood, but neuroinflammation might play a pivotal role. We hypothesise that systemic inflammation induced by the surgical trauma could activate the innate immune (glial) cells of the brain. This could lead to an exaggerated neuroinflammatory cascade, resulting in neuronal dysfunction and loss of neuronal cells. Therefore, the aims of this study are to assess neuroinflammation in vivo presurgery and postsurgery in patients undergoing major cardiac surgery and investigate whether there is a relationship of neuroinflammation to cognitive outcomes, changes to brain structure and function, and systemic inflammation. Methods and analysis: The FOCUS study is a prospective, single-centre observational study, including 30 patients undergoing elective on-pump CABG. Translocator protein (TSPO) positron emission tomography neuroimaging will be performed preoperatively and postoperatively using the second generation tracer 18 F-DPA-714 to assess the neuroinflammatory response. In addition, a comprehensive cerebral MRI will be performed presurgery and postsurgery, in order to discover newly developed brain and vascular wall lesions. Up to 6 months postoperatively, serial extensive neurocognitive assessments will be performed and blood will be obtained to quantify systemic inflammatory responses and peripheral immune cell activation. Ethics and dissemination: Patients do not benefit directly from engaging in the study, but imaging neuroinflammation is considered safe and no side effects are expected. The study protocol obtained ethical approval by the Medical Research Ethics Committee region Arnhem-Nijmegen. This work will be published in peer-reviewed international medical journals and presented at medical conferences. Trial registration number: NCT04520802 .
- Open Access
- 14 February 2021
- Published by Wiley in The Journal of Pathology
- Vol. 254 (4) , 307-331
COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID‐19 cases are characterised by a mild, self‐limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi‐organ failure (MOF). Progression of COVID‐19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS‐CoV‐2 infection and contribute to organ‐specific tissue damage. In this respect, dissecting currently available knowledge of COVID‐19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune‐mediated pathways during SARS‐CoV‐2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID‐19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence‐based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID‐19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID‐19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID‐19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
- 14 February 2021
- Published by Wiley in The Journal of Pathology
- Vol. 254 (4) , 307-331
Open AccessCOVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID‐19 cases are characterised by a mild, self‐limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi‐organ failure (MOF). Progression of COVID‐19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS‐CoV‐2 infection and contribute to organ‐specific tissue damage. In this respect, dissecting currently available knowledge of COVID‐19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune‐mediated pathways during SARS‐CoV‐2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID‐19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence‐based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID‐19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID‐19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID‐19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 10 December 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-12
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation. Methods: In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment. Results: Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) (p = 0.0002), ferritin (p = 0.009), and temperature (p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature (p = 0.03), white blood cell counts (p = 0.02), and plasma levels of ferritin (p = 0.003), procalcitonin (p = 0.001), creatinine (p = 0.01), and bilirubin (p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results. Conclusions: Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.
- 10 December 2020
- Published by Springer Nature in Critical Care
- Vol. 24 (1) , 1-12
Open AccessAnakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation. Methods: In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment. Results: Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) (p = 0.0002), ferritin (p = 0.009), and temperature (p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature (p = 0.03), white blood cell counts (p = 0.02), and plasma levels of ferritin (p = 0.003), procalcitonin (p = 0.001), creatinine (p = 0.01), and bilirubin (p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results. Conclusions: Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.
- Top Cited Papers
- 1 September 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (6) , 830-842
Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis
Rationale: Sepsis is characterized by a dysregulated immune response to infection. Norepinephrine, the cornerstone vasopressor used in septic shock, may contribute to immune dysregulation and impact host defense. Objectives: To investigate effects of norepinephrine and the alternative vasopressor vasopressin on the immune response and host defense. Methods: Leukocytes from six to nine donors were stimulated in the presence or absence of norepinephrine and vasopressin. A total of 190 C57BL/6J mice received a continuous infusion of norepinephrine or vasopressin via microosmotic pumps and were challenged with LPS or underwent cecal ligation and puncture. Thirty healthy volunteers were randomized to a 5-hour infusion of norepinephrine, vasopressin, or saline and intravenously challenged with LPS. The relationship between the norepinephrine infusion rate and the use of β-blockers and plasma cytokines was assessed in 195 patients with septic shock. Measurements and Main Results: Norepinephrine attenuated the production of proinflammatory mediators and reactive oxygen species and augmented antiinflammatory IL-10 production both in vitro and in LPS-challenged mice. Norepinephrine infusion during cecal ligation and puncture resulted in increased bacterial dissemination to the spleen, liver, and blood. In LPS-challenged volunteers, norepinephrine enhanced plasma IL-10 concentrations and attenuated the release of the proinflammatory cytokine IFN-γ–induced protein 10. Vasopressin exerted no immunomodulatory effects across these experimental setups. In patients, higher norepinephrine infusion rates were correlated with a more antiinflammatory cytokine balance, whereas β-blocker use was associated with a more proinflammatory cytokine balance. Conclusions: Norepinephrine dysregulates the immune response in mice and humans and compromises host defense. Therefore, it may significantly contribute to sepsis-induced immunoparalysis, whereas vasopressin does not have untoward immunologic effects.
- 1 September 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (6) , 830-842
Top Cited PapersNorepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis
Rationale: Sepsis is characterized by a dysregulated immune response to infection. Norepinephrine, the cornerstone vasopressor used in septic shock, may contribute to immune dysregulation and impact host defense. Objectives: To investigate effects of norepinephrine and the alternative vasopressor vasopressin on the immune response and host defense. Methods: Leukocytes from six to nine donors were stimulated in the presence or absence of norepinephrine and vasopressin. A total of 190 C57BL/6J mice received a continuous infusion of norepinephrine or vasopressin via microosmotic pumps and were challenged with LPS or underwent cecal ligation and puncture. Thirty healthy volunteers were randomized to a 5-hour infusion of norepinephrine, vasopressin, or saline and intravenously challenged with LPS. The relationship between the norepinephrine infusion rate and the use of β-blockers and plasma cytokines was assessed in 195 patients with septic shock. Measurements and Main Results: Norepinephrine attenuated the production of proinflammatory mediators and reactive oxygen species and augmented antiinflammatory IL-10 production both in vitro and in LPS-challenged mice. Norepinephrine infusion during cecal ligation and puncture resulted in increased bacterial dissemination to the spleen, liver, and blood. In LPS-challenged volunteers, norepinephrine enhanced plasma IL-10 concentrations and attenuated the release of the proinflammatory cytokine IFN-γ–induced protein 10. Vasopressin exerted no immunomodulatory effects across these experimental setups. In patients, higher norepinephrine infusion rates were correlated with a more antiinflammatory cytokine balance, whereas β-blocker use was associated with a more proinflammatory cytokine balance. Conclusions: Norepinephrine dysregulates the immune response in mice and humans and compromises host defense. Therefore, it may significantly contribute to sepsis-induced immunoparalysis, whereas vasopressin does not have untoward immunologic effects.
- Open Access
- 27 August 2020
- Published by Elsevier in Annals of Intensive Care
- Vol. 10 (1) , 115-11
The impact of critical illness on the expiratory muscles and the diaphragm assessed by ultrasound in mechanical ventilated children
- 27 August 2020
- Published by Elsevier in Annals of Intensive Care
- Vol. 10 (1) , 115-11
Open AccessThe impact of critical illness on the expiratory muscles and the diaphragm assessed by ultrasound in mechanical ventilated children
- Open Access
- 23 June 2020
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (6) , e16733
Prediction Model for Timing of Death in Potential Donors After Circulatory Death (DCD III): Protocol for a Multicenter Prospective Observational Cohort Study
Background: Controlled donation after circulatory death (cDCD) is a major source of organs for transplantation. A potential cDCD donor poses considerable challenges in terms of identification of those dying within the predefined time frame of warm ischemia after withdrawal of life-sustaining treatment (WLST) to circulatory arrest. Several attempts have been made to develop models predicting the time between treatment withdrawal and circulatory arrest. This time window determines whether organ donation can occur and influences the quality of the donated organs. However, the selected patients used for these models were not always restricted to potential cDCD donors (eg, patients with cancer or severe infections were also included). This severely limits the generalizability of those data. Objective: The objectives of this study are the following: (1) to develop a model predicting time to death within 60 minutes in potential cDCD patients; (2) to validate and update previous prediction models on time to death after WLST; (3) to determine timing and patient characteristics that are associated with prognostication and the decision-making process that leads to initiating end-of-life care; (4) to evaluate the impact of timing of family approach on organ donation approval; and (5) to assess the influence of variation in WLST processes on postmortem organ donor potential and actual postmortem organ donors. Methods: In this multicenter observational prospective cohort study, all patients admitted to the intensive care unit of 3 university hospitals and 3 teaching hospitals who met the criteria of the cDCD protocol as defined by the Dutch Transplant Foundation were included. The target of enrolment was set to 400 patients. Previously developed models will be refitted in our data set. To further update previous prediction models, we will apply least absolute shrinkage and selection operator (LASSO) as a tool for efficient variable selection to develop the multivariable logistic regression model. Results: This protocol was funded in August 2014 by the Dutch Transplant Foundation. We expect to have the results of this study in July 2020. Patient enrolment was completed in July 2018 and data collection was completed in April 2020. Conclusions: This study will provide a robust multimodal prediction model, based on clinical and physiological parameters, that can predict time to circulatory arrest in cDCD donors. In addition, it will add valuable insight in the process of WLST in cDCD donors and will fill an important knowledge gap in this essential field of health care. Trial Registration: ClinicalTrials.gov NCT04123275; https://clinicaltrials.gov/ct2/show/NCT04123275 International Registered Report Identifier (IRRID): DERR1-10.2196/16733
- 23 June 2020
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 9 (6) , e16733
Open AccessPrediction Model for Timing of Death in Potential Donors After Circulatory Death (DCD III): Protocol for a Multicenter Prospective Observational Cohort Study
Background: Controlled donation after circulatory death (cDCD) is a major source of organs for transplantation. A potential cDCD donor poses considerable challenges in terms of identification of those dying within the predefined time frame of warm ischemia after withdrawal of life-sustaining treatment (WLST) to circulatory arrest. Several attempts have been made to develop models predicting the time between treatment withdrawal and circulatory arrest. This time window determines whether organ donation can occur and influences the quality of the donated organs. However, the selected patients used for these models were not always restricted to potential cDCD donors (eg, patients with cancer or severe infections were also included). This severely limits the generalizability of those data. Objective: The objectives of this study are the following: (1) to develop a model predicting time to death within 60 minutes in potential cDCD patients; (2) to validate and update previous prediction models on time to death after WLST; (3) to determine timing and patient characteristics that are associated with prognostication and the decision-making process that leads to initiating end-of-life care; (4) to evaluate the impact of timing of family approach on organ donation approval; and (5) to assess the influence of variation in WLST processes on postmortem organ donor potential and actual postmortem organ donors. Methods: In this multicenter observational prospective cohort study, all patients admitted to the intensive care unit of 3 university hospitals and 3 teaching hospitals who met the criteria of the cDCD protocol as defined by the Dutch Transplant Foundation were included. The target of enrolment was set to 400 patients. Previously developed models will be refitted in our data set. To further update previous prediction models, we will apply least absolute shrinkage and selection operator (LASSO) as a tool for efficient variable selection to develop the multivariable logistic regression model. Results: This protocol was funded in August 2014 by the Dutch Transplant Foundation. We expect to have the results of this study in July 2020. Patient enrolment was completed in July 2018 and data collection was completed in April 2020. Conclusions: This study will provide a robust multimodal prediction model, based on clinical and physiological parameters, that can predict time to circulatory arrest in cDCD donors. In addition, it will add valuable insight in the process of WLST in cDCD donors and will fill an important knowledge gap in this essential field of health care. Trial Registration: ClinicalTrials.gov NCT04123275; https://clinicaltrials.gov/ct2/show/NCT04123275 International Registered Report Identifier (IRRID): DERR1-10.2196/16733
- Open Access
- 7 June 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (12) , 3574-3581
Determining the impact of timing and of clinical factors during end-of-life decision-making in potential controlled donation after circulatory death donors
- 7 June 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (12) , 3574-3581
Open AccessDetermining the impact of timing and of clinical factors during end-of-life decision-making in potential controlled donation after circulatory death donors
- Open Access
- 28 May 2020
- Published by Springer Nature in Intensive Care Medicine
- Vol. 46 (8) , 1653-1654
Recognizing and supporting morally injured ICU professionals during the COVID-19 pandemic
- 28 May 2020
- Published by Springer Nature in Intensive Care Medicine
- Vol. 46 (8) , 1653-1654
Open AccessRecognizing and supporting morally injured ICU professionals during the COVID-19 pandemic
- Open Access
- 19 October 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Prediction Model for Timing of Death in Potential Donors After Circulatory Death (DCD III): Protocol for a Multicenter Prospective Observational Cohort Study (Preprint)
BACKGROUND Controlled donation after circulatory death (cDCD) is a major source of organs for transplantation. A potential cDCD donor poses considerable challenges in terms of identification of those dying within the predefined time frame of warm ischemia after withdrawal of life-sustaining treatment (WLST) to circulatory arrest. Several attempts have been made to develop models predicting the time between treatment withdrawal and circulatory arrest. This time window determines whether organ donation can occur and influences the quality of the donated organs. However, the selected patients used for these models were not always restricted to potential cDCD donors (eg, patients with cancer or severe infections were also included). This severely limits the generalizability of those data. OBJECTIVE The objectives of this study are the following: (1) to develop a model predicting time to death within 60 minutes in potential cDCD patients; (2) to validate and update previous prediction models on time to death after WLST; (3) to determine timing and patient characteristics that are associated with prognostication and the decision-making process that leads to initiating end-of-life care; (4) to evaluate the impact of timing of family approach on organ donation approval; and (5) to assess the influence of variation in WLST processes on postmortem organ donor potential and actual postmortem organ donors. METHODS In this multicenter observational prospective cohort study, all patients admitted to the intensive care unit of 3 university hospitals and 3 teaching hospitals who met the criteria of the cDCD protocol as defined by the Dutch Transplant Foundation were included. The target of enrolment was set to 400 patients. Previously developed models will be refitted in our data set. To further update previous prediction models, we will apply least absolute shrinkage and selection operator (LASSO) as a tool for efficient variable selection to develop the multivariable logistic regression model. RESULTS This protocol was funded in August 2014 by the Dutch Transplant Foundation. We expect to have the results of this study in July 2020. Patient enrolment was completed in July 2018 and data collection was completed in April 2020. CONCLUSIONS This study will provide a robust multimodal prediction model, based on clinical and physiological parameters, that can predict time to circulatory arrest in cDCD donors. In addition, it will add valuable insight in the process of WLST in cDCD donors and will fill an important knowledge gap in this essential field of health care. CLINICALTRIAL ClinicalTrials.gov NCT04123275; https://clinicaltrials.gov/ct2/show/NCT04123275 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/16733
- 19 October 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrediction Model for Timing of Death in Potential Donors After Circulatory Death (DCD III): Protocol for a Multicenter Prospective Observational Cohort Study (Preprint)
BACKGROUND Controlled donation after circulatory death (cDCD) is a major source of organs for transplantation. A potential cDCD donor poses considerable challenges in terms of identification of those dying within the predefined time frame of warm ischemia after withdrawal of life-sustaining treatment (WLST) to circulatory arrest. Several attempts have been made to develop models predicting the time between treatment withdrawal and circulatory arrest. This time window determines whether organ donation can occur and influences the quality of the donated organs. However, the selected patients used for these models were not always restricted to potential cDCD donors (eg, patients with cancer or severe infections were also included). This severely limits the generalizability of those data. OBJECTIVE The objectives of this study are the following: (1) to develop a model predicting time to death within 60 minutes in potential cDCD patients; (2) to validate and update previous prediction models on time to death after WLST; (3) to determine timing and patient characteristics that are associated with prognostication and the decision-making process that leads to initiating end-of-life care; (4) to evaluate the impact of timing of family approach on organ donation approval; and (5) to assess the influence of variation in WLST processes on postmortem organ donor potential and actual postmortem organ donors. METHODS In this multicenter observational prospective cohort study, all patients admitted to the intensive care unit of 3 university hospitals and 3 teaching hospitals who met the criteria of the cDCD protocol as defined by the Dutch Transplant Foundation were included. The target of enrolment was set to 400 patients. Previously developed models will be refitted in our data set. To further update previous prediction models, we will apply least absolute shrinkage and selection operator (LASSO) as a tool for efficient variable selection to develop the multivariable logistic regression model. RESULTS This protocol was funded in August 2014 by the Dutch Transplant Foundation. We expect to have the results of this study in July 2020. Patient enrolment was completed in July 2018 and data collection was completed in April 2020. CONCLUSIONS This study will provide a robust multimodal prediction model, based on clinical and physiological parameters, that can predict time to circulatory arrest in cDCD donors. In addition, it will add valuable insight in the process of WLST in cDCD donors and will fill an important knowledge gap in this essential field of health care. CLINICALTRIAL ClinicalTrials.gov NCT04123275; https://clinicaltrials.gov/ct2/show/NCT04123275 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/16733